Insmed Inc
Company Profile
Business description
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Contact
700 US Highway 202/206
BridgewaterNJ08807
USAT: +1 908 977-9900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
912
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,754.70 | 49.70 | 0.57% |
CAC 40 | 7,255.42 | 18.53 | 0.26% |
DAX 40 | 20,016.75 | 83.13 | 0.42% |
Dow JONES (US) | 44,705.53 | 76.47 | -0.17% |
FTSE 100 | 8,359.41 | 46.52 | 0.56% |
HKSE | 19,746.32 | 196.03 | 1.00% |
NASDAQ | 19,480.91 | 76.96 | 0.40% |
Nikkei 225 | 39,248.86 | 735.84 | 1.91% |
NZX 50 Index | 12,962.13 | 131.05 | -1.00% |
S&P 500 | 6,049.88 | 2.73 | 0.05% |
S&P/ASX 200 | 8,495.20 | 47.30 | 0.56% |
SSE Composite Index | 3,378.81 | 14.82 | 0.44% |